This observational study, called the Alpha-1 Coded Testing (ACT) Study, is looking at genetic testing for Alpha-1 Antitrypsin Deficiency (AATD). AATD is a genetic condition that can lead to lung and liver disease. The study uses a home fingerstick test to check your Alpha-1 Antitrypsin Genotype (your genetic makeup for AATD). Researchers want to understand why people get tested, what they think about the risks and benefits of testing, and how AATD affects other health conditions. You can join if you are at risk for AATD due to symptoms or family history, and haven't already had AATD genotype and level testing. The study aims to enroll 50,000 participants. The current status of the study is unclear.

Study design

This is an observational study with a planned enrollment of 50,000 participants. It uses a coded testing procedure to return results confidentially.

What's involved

Participants will complete a home fingerstick test for Alpha-1 Antitrypsin Genotype and answer a structured questionnaire before and after testing.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, questionnaire responses, is measured before and after testing.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.